A novel mouse model of hypertensive emergency with multiorgan microvascular disease implicating the VEGFA/sFlt-1 balance

This study identifies the 129Sv mouse strain as a novel model of hypertensive emergency that exhibits multi-organ microvascular injury independent of blood pressure levels, driven by a dysregulated VEGFA/sFlt-1 balance that can be partially reversed by PlGF-2 supplementation.

The Gist

The Big Picture: Why Do Some People Crash While Others Don't?

Imagine you are driving two identical cars up a very steep, dangerous mountain road. Both cars have their engines revving at the exact same high speed (high blood pressure).

• Car A (The C57BL/6J mouse): It handles the climb just fine. It gets a little tired, but it keeps driving.
• Car B (The 129Sv mouse): Suddenly, its brakes fail, the engine overheats, the tires blow out, and the car crashes.

The big mystery in medicine has always been: Why does Car B crash when Car A doesn't, even though they are both going the same speed?

This paper solves that mystery. The researchers discovered that the crash isn't just about how fast you are going (blood pressure); it's about the internal wiring and the "glue" holding the car together. In Car B, the glue is weak and starts to dissolve, causing the whole vehicle to fall apart.

---

The Cast of Characters

1. The Villain (High Blood Pressure): This is the stressor. In the study, they used a drug (Angiotensin II) and salty food to force the mice's blood pressure up to dangerous levels.
2. The "Glue" (VEGFA): Think of this as the super-strong adhesive that keeps the tiny blood vessels (capillaries) sealed tight. It keeps blood inside the pipes and stops it from leaking into the brain, eyes, or kidneys.
3. The "Glue-Eater" (sFlt-1): This is a rogue protein that acts like a solvent. It hunts down the "Glue" (VEGFA) and eats it, leaving the blood vessels weak and leaky.
4. The Rescue Team (PlGF-2): This is a special chemical that acts like a shield. It grabs the "Glue-Eater" before it can destroy the glue, saving the blood vessels.

---

What Happened in the Experiment?

The scientists took two types of mice and forced them into a "hypertensive emergency" (a sudden, life-threatening spike in blood pressure).

1. The Crash (Organ Failure)
The "Car B" mice (129Sv strain) didn't just get high blood pressure; they developed a total system failure.

• Kidneys: They started leaking protein (like a sieve with holes).
• Eyes: They had bleeding in the retina (like a burst pipe in a water garden).
• Heart: Their hearts started skipping beats and eventually stopped.
• The Result: They died quickly.

The "Car A" mice (B6J strain) had the same high blood pressure, but their internal "glue" held strong. They survived with no major damage.

2. The Smoking Gun (The Glue-Eater)
The researchers looked inside the "Car B" mice and found a massive amount of the "Glue-Eater" (sFlt-1) floating in their blood. It was so high it looked like the levels seen in a dangerous pregnancy condition called preeclampsia.

• The Theory: The high blood pressure triggered the "Glue-Eater" to go wild. It ate all the "Glue," causing the blood vessels to become leaky and burst.

3. The Rescue Mission
To prove this was the cause, the scientists gave the "Car B" mice a dose of the "Rescue Team" (PlGF-2).

• The Result: The "Rescue Team" caught the "Glue-Eater." The blood vessels stopped leaking, the kidneys healed, the eyes stopped bleeding, and the mice survived!

4. Who is to Blame? (The Bone Marrow Test)
The scientists wondered: Is the "Glue-Eater" coming from the immune system (blood cells) or the body tissues?
They did a swap: They took the bone marrow (the factory for blood cells) from a tough "Car A" mouse and put it into a weak "Car B" mouse, and vice versa.

• The Finding: It was a team effort. You needed both the weak blood cells and the weak body tissues to create the perfect storm. If you fixed just one part, the mouse still got sick, but not as bad. This means the problem is systemic—it's in the whole system, not just one part.

5. The Microscope View (Single-Cell Sequencing)
They looked at the individual cells in the kidney using a high-tech microscope (RNA sequencing). They saw that in the sick mice, the cells lining the blood vessels were essentially "shutting down." They stopped making energy and stopped repairing themselves. When they gave the "Rescue Team," the cells woke up and started working again.

---

Why Does This Matter? (The Takeaway)

For a long time, doctors thought that if you just lowered the blood pressure, the patient would be fine. This paper says: "Not necessarily."

• The Analogy: If your house is on fire because the wiring is faulty, turning down the thermostat won't stop the fire. You have to fix the wiring.
• The Discovery: Some people are genetically wired to have a "weak glue" system when they get stressed. Even if their blood pressure is the same as a healthy person, their blood vessels might burst because their "Glue-Eater" is too active.
• The Future: This opens a new door for treatment. Instead of just lowering blood pressure, doctors might one day give patients a "Rescue Team" drug (like PlGF-2) to protect their blood vessels from leaking. This could save lives for people who are prone to these sudden, catastrophic health events.

In a Nutshell

This study found a new mouse model that perfectly mimics a human medical emergency. They discovered that genetics play a huge role in who survives high blood pressure and who doesn't. The culprit is a chemical imbalance that destroys the "glue" holding blood vessels together. By fixing that imbalance, they were able to save the mice, offering hope for a new way to treat humans with hypertensive emergencies.

Technical Summary

1. Problem Statement

Hypertensive Emergency (HTEM) is a life-threatening condition characterized by abrupt, severe blood pressure (BP) elevation accompanied by acute multi-organ damage (Target Organ Damage or TOD), including the kidneys, eyes, and heart.

• The Gap: While chronic hypertension is well-studied, the mechanisms predisposing only a subset of hypertensive individuals to HTEM remain unclear. Current animal models (mostly rat-based) fail to faithfully recapitulate the acute, multi-organ microvascular injury and sudden mortality seen in human HTEM.
• The Hypothesis: The authors propose that susceptibility to HTEM is not solely driven by BP levels but by BP-independent genetic factors and a dysregulated angiogenic balance (specifically the VEGFA/sFlt-1 axis), similar to mechanisms observed in preeclampsia.

2. Methodology

The study utilized a comparative approach between two mouse strains: C57BL/6J (B6J), known for resistance to hypertensive kidney injury, and 129S2/SvPasCrl (129Sv).

• Induction of Hypertension: Male mice were subjected to severe hypertension via subcutaneous infusion of Angiotensin II (Ang II, 1 µg/kg/min) combined with a high-salt diet (3% NaCl) for 7–14 days.
• Phenotyping & Imaging:
  • Telemetry: Continuous BP monitoring to confirm similar BP levels between strains.
  • Renal Function: Urinary albumin-to-creatinine ratio (ACR), plasma albumin, and Blood Urea Nitrogen (BUN).
  • Histology: Light microscopy (Masson's trichrome) and Transmission Electron Microscopy (TEM) for glomerular filtration barrier (GFB) ultrastructure.
  • Retinal Imaging: In vivo fundus imaging and Optical Coherence Tomography (OCT) to assess hemorrhages, exudates, and subretinal swelling.
  • Cardiac Assessment: Echocardiography for hemodynamics and continuous ECG monitoring for arrhythmias (QTc prolongation, ventricular tachycardia, atrial fibrillation).
  • Vascular Permeability: Evans Blue dye assay and wet-to-dry weight ratios to measure edema and leakage.
• Mechanistic Interventions:
  • Bone Marrow Transplantation (BMT): Using CD45.1/CD45.2 congenic markers to swap bone marrow between B6J and 129Sv strains, distinguishing the roles of hematopoietic vs. non-hematopoietic cells.
  • Therapeutic Rescue: Administration of recombinant human Placental Growth Factor (rhPlGF-2) to hypertensive 129Sv mice to neutralize excess soluble fms-like tyrosine kinase-1 (sFlt-1).
  • Single-Cell RNA Sequencing (scRNA-seq): Performed on isolated glomeruli to analyze transcriptomic changes in endothelial cells, podocytes, and mesangial cells.

3. Key Contributions

1. Novel Mouse Model: The first mouse model to faithfully reproduce the lethal, multi-organ microvascular phenotype of human HTEM, including retinal hemorrhages, acute kidney injury (AKI), and fatal arrhythmias.
2. Genetic Susceptibility: Demonstrated that HTEM susceptibility is BP-independent; 129Sv mice developed lethal multi-organ failure despite having BP levels identical to resistant B6J mice.
3. Mechanistic Discovery: Identified the VEGFA/sFlt-1 imbalance as the central driver of endothelial dysfunction in HTEM, drawing a parallel between HTEM and preeclampsia.
4. Cellular Source Mapping: Used BMT to show that both hematopoietic and non-hematopoietic (tissue) compartments contribute to the pathological overproduction of sFlt-1.

4. Key Results

• Differential Survival: Under Ang II + high salt, B6J mice survived with no organ damage. In contrast, 129Sv mice exhibited high mortality starting ~1 week after hypertension onset.
• Multi-Organ Damage in 129Sv:
  • Kidney: Severe albuminuria, AKI (elevated BUN), podocyte foot process effacement, endotheliosis, and glomerular thrombotic microangiopathy (TMA)-like lesions.
  • Eye: Retinal hemorrhages, hard exudates, subretinal swelling, and capillary rarefaction.
  • Heart: Reduced stroke volume, cardiac output, and severe arrhythmias (QTc prolongation, ventricular tachycardia, atrial fibrillation). Two mice died of cardiac arrest.
  • Systemic: Evidence of hemoconcentration and widespread vascular permeability (Edema).
• The Angiogenic Imbalance:
  • Hypertensive 129Sv mice showed markedly elevated plasma sFlt-1 levels (comparable to preeclampsia), whereas B6J mice did not.
  • Rescue Experiment: Treatment with rhPlGF-2 (which binds and neutralizes sFlt-1) in hypertensive 129Sv mice partially reversed albuminuria, preserved glomerular ultrastructure, and reduced retinal hemorrhages.
• Bone Marrow Transplantation:
  • Mice with 129Sv bone marrow in a B6J host (and vice versa) showed intermediate phenotypes.
  • Conclusion: Both hematopoietic (immune) and non-hematopoietic (tissue) 129Sv cells are required to drive the full sFlt-1 overproduction and organ injury.
• Transcriptomics (scRNA-seq):
  • Glomerular Endothelial Cells (GEnCs): Showed profound downregulation of angiogenic, metabolic, and stress-response pathways.
  • Effect of PlGF: PlGF treatment partially restored these pathways, confirming that the injury is driven by the loss of pro-angiogenic signaling.
  • Inflammation: Surprisingly, the endothelial inflammatory signature (NF-κB) was decreased, suggesting the primary driver is metabolic/angiogenic failure rather than classic inflammation.

5. Significance and Clinical Implications

• Paradigm Shift: The study challenges the view that HTEM is purely a hemodynamic event, highlighting that genetic susceptibility and vascular fragility are critical determinants.
• Therapeutic Target: The identification of the VEGFA/sFlt-1 axis suggests that modulating angiogenic balance (e.g., using PlGF or anti-sFlt-1 strategies) could be a novel therapeutic approach to prevent acute target organ damage in severe hypertension, distinct from standard antihypertensive therapy.
• Model Utility: This 129Sv model provides a robust platform for future genetic and pharmacological studies to dissect the mechanisms of HTEM, a condition currently lacking effective specific treatments beyond BP control.
• Preeclampsia Link: The findings suggest a shared pathophysiology between HTEM and preeclampsia, potentially allowing for cross-disciplinary insights into hypertensive disorders.